National Health and Health Commission issued a heavy notice, "limited resistance order" to upgrade again!

The Pharmaceutical Network Policy and Regulations recently, the National Health and Care Commission issued a notice that medical institutions at all levels are required to continue to do a good job in the clinical application of antimicrobial drugs management.
, it is clearly stated that general hospitals above level 2 have set up infectious diseases departments in accordance with the regulations, and by the end of 2020 to treat bacterial fungal infections as the main disease of infection areas or medical groups.
At the same time, medical institutions should optimize the supply catalogue of antimicrobial drugs in conjunction with the "1 plus X" drug use model guided by essential drugs.
more crucially, the Notice also requires that doctors and pharmacists at or above the secondary level be regularly trained in clinical application knowledge and standardized management of antimicrobials.
physicians may not grant the right to prescribe antimicrobial drugs without training and passing the examination of this institution. at the same time
, the hospital may not grant the corresponding prescription authority solely on the basis of the doctor's title.
from the above, compared to the previous "restriction order" policy, this time the new rules are obviously more severe.
also indicates that physicians without training and assessment pass, not to use antimicrobial drugs, hospitals may not because a physician has obtained a senior title on the grant of the physician and high-level antimicrobial use rights.
in fact, with bacterial resistance becoming a world problem and began to expand from the field of health to the political and economic fields, China in order to strengthen the clinical application management of antimicrobial drugs, effectively curb bacterial resistance, in August 2012 began to implement the "clinical application management measures of antimicrobial drugs", also known as the "restriction order."
Measures, according to safety, efficacy, bacterial resistance, price and other factors, the antimicrobial drugs are divided into three levels: non-restricted use level, restricted use level and special use level.
and published a list of "non-limited drugs", drugs outside the list should be classified as "restricted use" and "special use level", requiring intermediate or higher titles in order to use.
then in September 2016, the National Health and Family Planning Commission, the National Development and Reform Commission and other 14 departments jointly issued the National Action Plan to Curb Bacterial Resistance (2016-2020), which the industry considered to mark a further escalation of the "restraint order".
November 26, 2019, the National Health and Planning Commission issued the Notice on continuing to do a good job in the management of the clinical application of antimicrobial drugs, further clarifying that the main person in charge of medical institutions is the primary responsible person for the management of antimicrobial drugs.
provides that the institution's training and assessment of "antimicrobial drug standard use" qualified physicians, can be granted the corresponding antimicrobial drug prescription rights, may not be based solely on the title of physician to grant prescription authority.
in short, with the continuous upgrading of the "restriction order", the phenomenon of clinical abuse of antibiotics is gradually being effectively controlled in China through the nationwide closure of outpatient infusions and restrictions on the clinical use of large varieties such as carbon penicillin antibiotics.
but at the same time, some pharmaceutical companies infusion business revenue has also seen a significant decline.
in this environment, Lilly announced in April 2019 that it would sell its antibiotic products, Skelore (cephaloc capsules) and Stable (injection of amphiin hydrochloride), to etonal medicine in Chinese mainland.
in general, under the pressure of "restriction order", the future prescription of antimicrobial drugs will be greatly restricted, the antimicrobial industry will enter the era of micro-profit.
and the old big infusion enterprises, such as Collon Pharmaceuticals, Shijiazhuang four drugs, China Resources Double Crane, etc., also need to accelerate the pursuit of transformation.
.